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Abstract
Objective: Extracorporeal membrane oxygenation (ECMO) in our institution resulted in near total
mortality prior to the establishment of an algorithm-based program in July 2010. We hypothesized that
an algorithm based ECMO program improves the outcome of patients with acute myocardial infarction
complicated with cardiogenic shock.
Methods: Between March 2003 and July 2013, 29 patients underwent emergent catheterization for acute
myocardial infarction due to left main or proximal left anterior descending artery occlusion complicated
with cardiogenic shock (defined as systolic blood pressure < 90mmHg despite multiple inotropes, +balloon pump, lactic acidosis). Of 29 patients, 15 patients were before July 2010 (Group 1, old program),
14 patients were after July 2010 (Group 2, new program).
Results: There were no significant differences in the baseline characteristics, including age, sex, coronary
risk factors and left ventricular ejection fraction, between the two groups.

Cardiopulmonary resuscitation

prior to ECMO was performed in 2 cases (13%) in Group 1 and 4 cases (29%) in Group 2. ECMO
support was performed in 1 case (6.7%) in Group 1 and 6 cases (43%) in Group 2. The 30-day survival
of Group 1 vs. Group 2 was 40% vs. 79% (p = 0.03), and one-year survival rate was 20% vs. 56%
(p=0.01). The survival rate for patients who underwent ECMO was 0% in Group 1 vs. 83% in Group 2
(p = 0.09). In Group 2, the mean duration on ECMO was 9.8 ± 5.9 days.

Of the 6 patients who

required ECMO in Group 2, 100% were successfully weaned off ECMO or were bridged to ventricular
assist device implantation.
Conclusions: Initiation of an algorithm based ECMO program improved the outcomes in patients with
acute myocardial infarction complicated by cardiogenic shock.
(Word count of abstract: 311)

Key words: cardiac surgery, extracorporeal membrane oxygenation, acute coronary syndrome
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Introduction
Cardiogenic shock occurs in 5 - 10% of the patients with acute myocardial infarction (AMI), and
its mortality is reported to be 40 - 50% (1-3).

AMI caused by left main (LM) occlusion or proximal left

anterior descending artery (pLAD) occlusion carries an increased risk of mortality, compared to mid to
distal left anterior descending artery, circumflex, or right coronary artery occlusion (4, 5). The volume of
the myocardium at risk is greater in LM and pLAD lesions than in the others, which can lead to
hemodynamic instability with worse outcome (5, 6). Inotropes, vasopressors, and intra-aortic balloon
pump (IABP) have been used as the first line support for the hemodynamics during emergent
revascularization, either by percutaneous coronary intervention (PCI) or coronary artery bypass grafting
(CABG). Recently, reports of using venoarterial extracorporeal membrane oxygenation (VA-ECMO) to
stabilize the hemodynamics during the period of evolving AMI have been published (7, 8).

In our

institution, a new ECMO program was started in July 2010, which consists of a dedicated intensive care
unit (ICU), multidisciplinary providers (intensivists, mid-level providers, nurses, and perfusionists),
educational programs (didactic sessions, hands-on training, and competency tests), and the introduction of
new technologies and the development of treatment algorithms.

We hypothesized that our new ECMO

program improved the outcome of patients with acute myocardial infarction caused by LM or pLAD
lesion complicated by cardiogenic shock.
Methods
Patients: Using our catheterization laboratory database, patients with AMI due to left main or proximal
left anterior descending artery occlusion complicated with cardiogenic shock were identified. AMI was
defined as prolonged (> 30 minutes) chest pain or equivalent symptoms and electrocardiographic changes
(9). Cardiogenic shock was defined as systolic blood pressure < 90 mm Hg for more than 30 to 60
minutes or the need for escalating inotropes, vasopressors, or IABP to maintain systolic blood pressure >
90 mm Hg.

Demographics, hemodynamics and biochemical values were collected retrospectively from

patients’ charts and other databases after approval of internal review board. The survival status was
obtained from a Social Security Death Index search. Between March 2003 and July 2013, 29 adult
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patients (age > 18 years) underwent emergent catheterization for AMI due to LM or pLAD occlusion,
complicated with cardiogenic shock.

Patients who had coronary artery bypass surgery in the past,

patients with circumflex lesion or mid to distal LAD lesion which was considered to be the culprit of the
cardiogenic shock, were excluded. The patients were divided into two groups: Group 1 before July 2010
(old program) and Group 2 after July 2010 (new program).
The Vasoactive-inotropic score was calculated using the following formula: dopamine
[ug/kg/min] + dobutamine [ug/kg/min] + 10,000 x vasopressin [U/kg/min] + 10 x milrinone [ug/kg/min] +
100 x epinephrine [ug/kg/min] + 100 x norepinephrine [ug/kg/min]) (10).
Indication for ECMO: ECMO consult was obtained if the patient had persistent profound cardiogenic
shock, despite high doses of multiple intravenous inotropes and vasopressors, and IABP/Impella support,
and/or ventricular tachycardia/fibrillation refractory to anti-arrhythmic medications and cardioversion.
Profound cardiogenic shock was defined as systolic blood pressure < 90mmHg despite fluid resuscitation
and being placed on high doses of multiple inotropes and evidence of decreased organ perfusion
(increased lactate, low urine output, cool and diaphoretic extremities, and altered mental status).

An

Intensivist, cardiothoracic surgical fellow, or a mid-level provider rapidly assessed the patient for the
indication. Inability to access the groin vessels, presence of a terminal disease process and
do-not-resuscitate orders, un-witnessed cardiac arrest and downtime were contraindications for ECMO in
patients with profound cardiogenic shock.

Age over 75 was considered a relative contraindication.

VA-ECMO was inserted either in the catheterization laboratory or at the bedside under fluoroscopy
guidance.
ECMO (Equipment and cannulation technique): Since the new ECMO program was initiated (11), our
ECMO system consisted of a centrifugal pump (Rota flow, Maquet, San Jose, California), PMP
oxygenator (Quadrox D ,Maquet), and a heparin coated circuit with minimal access points. The portable
CardioHelp system (Maquet) was also utilized to transport patients from outside facilities.

Heparin

coated cannulas (arterial 16 - 22 Fr, venous 18 - 24 Fr, Edwards Life Sciences, Irvine, CA) were inserted
percutaneous through the femoral veno-arterial route using the Seldinger technique (12). The tip of the
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arterial cannula is directed to the common iliac artery, and the tip of the venous cannula is directed into
mid-right atrium.

In all patients, a distal limb perfusion catheter (4 Fr or 5Fr) was inserted percutaneous

in the superficial femoral artery for distal limb perfusion.
Management and Monitoring: Anticoagulation was started 6-12 hours after ECMO cannulation using
heparin with a goal PTT level of 50 - 60 sec. Patients were sedated adequately using continuous
infusions of midazolam and fentanyl; paralysis with vecuronium was given whenever necessary.
ECMO flow rate is set so as to achieve a goal of > 2.2 L/min/m2.

The

Inotropes (epinephrine, milrinone,

dobutamine) were weaned off and IABP was discontinued after ECMO stabilization. Vasopressors
(neosynephrine, vasopressin, norepinephrine) were used to maintain a mean arterial pressure of 60 - 80
mmHg.

The Swan-Ganz catheter was removed once ECMO was initiated due to the risk of migration

and possible perforation of the pulmonary artery.

Monitoring of the heart was done periodically with a

miniaturized hemodynamic transesophageal echocardiography probe (hTEE; ImaCor, Garden City, NY) to
observe the cardiac function and the degree of distension and decompression (13). In addition, to ensure
tissue perfusion, cerebral oximetry and lower limb oximetry was monitored routinely using near-infrared
spectroscopy (INVOS, Covidien, Mansfield, MA or FORESIGHT, CAS Medical Systems, Branford, CT)
(14). Patients who had cardiac arrest before the initiation of ECMO were actively cooled to 33°C within
3 hours, and maintained with a cooling device (Arctic Sun conductive cooling system [Medivance, Inc.,
Louisville, CO]).

After 24 hours of cooling, patients were rewarmed 0.10-0.20° C every 1 hour.

Blood

products were transfused to maintain a hemoglobin of 8 - 10 g/dl, platelet count of 80,000 - 100,000 µl/ml.
Ventilator setting was minimized; tidal volume of 4 - 6 mL/kg, frequency of 8 - 10 /min, positive end
expiratory pressure of 5 cm H2O, and an FiO2 of 0.40 - 0.60.

Circuit exchange was considered when

arterial thrombus was seen in the circuit, or if there was unexplained hemolysis or inadequate oxygenation.
Discontinuation of ECMO and withdrawal of care were discussed with the family if irreversible
neurological damages were confirmed by head CT scan and neurological consultation.
Weaning from ECMO and removal: We considered weaning from ECMO when (1) the oxygenation
was adequate on 50% FiO2 from ECMO and ventilator, (2) volume status is optimized, (3) resolution of
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pre-ECMO organ dysfunction, and (4) afebrile (15). The anticoagulation was titrated to a PTT level of
60 to 70 seconds to avoid thrombotic complications while decreasing ECMO flow during the weaning trial
(15). The weaning trials were done over a 4-6 hour period, which consists of 4 stages; the heart function
and volume status was monitored continuously with the hTEE probe as described previously. ECMO was
removed in the operating room with an open repair. Thrombectomy and/or a patch repair of the artery
with a saphenous vein are done if required. A layer of fascia was closed over the vessels, the skin was
left open, and a vacuum assisted closure device (VAC) was placed, as the wound will not be completely
sterile.

If there was no recovery of the myocardium 7 to 10 days after ECMO placement, and the patient

was not a candidate for ventricular assist device, total artificial heart, or a transplant, an end of life
discussion was held with palliative care support.
Statistical analysis: Statistical analyses were conducted using R-environment (R version 3.0.2, R
Foundation for Statistical Computing, Vienna, Austria).

Continuous variables were expressed as mean ±

standard deviation (SD), and compared with standard t-test.

Categorical variables were expressed as

counts and percentages, and Chi-square test was used for comparisons. Kaplan-Meier survival curves
were generated to assess survival, and the survival was compared between the groups using the log-rank
test. The end-point for the survival analysis was death for any reason. P value less than 0.05 was
considered significant.
Results
Baseline characteristics: There were 15 patients were before July 2010 (Group 1, old program) and 14
patients after July 2010 (Group 2, new program). There were no significant differences in the baseline
characteristics, including age, sex, body-mass index, or coronary risk factors between the two groups
(Table 1).

Left main disease was the culprit lesion in 2 patients in Group 1 and 3 patients in Group 2.

The remainder of patients had a proximal LAD lesion. 6 patients in Group 1 and 5 patients in Group 2
received at least one episode of CPR prior to or within the catheterization laboratory. ECMO support
was performed in 1 case (6.7%) in Group 1 and 6 cases (43%) in Group 2.
Initial treatment: Treatments for the two groups are summarized in Table 2. 11 patients in Group 1 and

8

9 patients in Group 2 underwent emergency PCI, and 4 patients in Group 1 and 3 patients in Group 2
underwent emergency CABG. One patient in Group1 underwent mitral valve replacement and VSD
repair at the time of CABG. Of the 7 patients that required ECMO support, ECMO was initiated just
before revascularization in 2 patients, just after revascularization in 2 patients. 3 patients were placed on
ECMO more than 24 hours after revascularization.
ECMO data: ECMO support was performed in 1 case (6.7%) in Group 1 and 6 cases (43%) in Group 2 (p
< 0.05). The indications for ECMO were E-CPR in 3, unstable hemodynamics/high dose inotropes in 3,
and recurrent ventricular tachyarrhythmia in 1. The patients who were placed on ECMO in Group 2 had
a higher vasoactive-inotropic score compared to the non-ECMO patients (104.4 ± 122.0 vs. 31.9 ± 44.7 p
= 0.14). Although not statistically significant, lab values showed a trend towards improvement within 24
hours after initiation of ECMO (Table 3). In Group 2, the mean duration on ECMO was 9.8 ± 5.9 days (1
- 18 days).

There were no deaths among the patients who underwent ECMO in Group 2. The

complications that occurred during ECMO support are summarized in Table 4.
Survival results: The 30-day survival rate of Group 1 vs. Group 2 was 40% vs. 79% (p = 0.03, Figure
1). The cause of death in each group is listed on Table 5.

All of the 6 patients who required ECMO in

Group 2 were successfully weaned off ECMO; 2 patients were bridged to implantation of left ventricular
assist device, and 4 patients had total cardiac function recovery. The survival rate of Group 1 vs. Group 2
who underwent ECMO was 0% vs. 83% (p = 0.09, Figure 1).

In Group 2, among the 5 patients who had

CPR, 3 patients were placed on ECMO, 1 patient had withdrawal of care because of age (87 years old),
and another patient had withdrawal of care because of the prolonged CPR before arrival to our institution.
Kaplan-Meier survival and log-rank analysis showed significantly improved mid-term survival in Group 2
with a mean follow-up period of 11.8 ± 16.1 months (p = 0.01, Figure 2). The 1-year survival of Group 1
and Group 2 was, 20.0% and 56%, respectively.
Discussion
The main findings of the present study are (1) that an algorithm based ECMO program with
dedicated personnel improved short term and mid term survival in patients who had cardiogenic shock due
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to left main or proximal LAD, (2) initiation of ECMO was able to improve the hemodynamics and the
organ dysfunction due to cardiogenic shock, and (3) ECMO was performed and managed with a relatively
low complication rate.
Even though the target vessel is revascularized with PCI or CABG, stunned or hibernating
myocardium may develop and it takes 7 - 10 days to recover.
the cardiac function.

Reperfusion injury may further deteriorate

Poor hemodynamics during this period will reduce coronary perfusion with

resultant poor cardiac function and pulmonary edema. The subsequent result is poor oxygen supply to not
only the myocardium but also to other vital organs, resulting in multiple organ failure.

Adequate

hemodynamic support with ECMO will improve oxygen and blood supply and theoretically improve
survival.

In addition, ECMO will reduce the myocardial work-load and reduce oxygen consumption by

unloading the heart. Intervention to the LM or pLAD may be difficult due to arrhythmias and
hypotension; however, supporting the hemodynamics with ECMO will enable the cardiologist to achieve
complete revascularization. Inotropes and vasopressors may cause vasoconstriction, tissue ischemia and
potentially fatal arrhythmias, but in the majority of times these medications can be discontinued or
decreased within 24 hours of the initiation of ECMO. We also discontinue IABP after the initiation of
ECMO, as we believe there are no benefits in the use of IABP during ECMO. Park et al. reported that
the combined use of IABP with ECMO did not improve in-hospital survival (16). IABP may increase
coronary blood flow during diastole, but will cause intermittent aortic occlusion, which competes with the
flow from ECMO.
AMI with cardiogenic shock caused by LM, pLAD lesion carries a high mortality. Trzeciak et
al. reported that the in-hospital mortality when the infarct related artery was LM, LAD, LCx, RCA was
64.7%, 41.0%, 36.0%, and 30.8%, respectively. The 12-month mortality was 77.7%, 58.2%, 55.1%, and
45.0%, respectively (4). Although in their report, the LAD itself was not significantly related to
increased mortality, cardiac arrest during hospitalization was most commonly noted in the LM and LAD
groups (4).

Brener et al. reported that patients who had AMI caused by proximal LAD had higher

frequency of having a Killip class > 1 heart failure, ejection fraction < 40%, and mortality, compared to
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patients who had AMI due to a mid LAD lesion (5). This result was thought to be due to larger infarcts
in patients with proximal LAD occlusion.
Initiation of an algorithm based ECMO program in our institution resulted in an improved
outcome in patients with acute myocardial infarction complicated by cardiogenic shock due to LM or
pLAD lesions. We believe the patients who were placed on ECMO would not have survived traditional
treatment.

Although the numbers of our patients are low, the 30-day survival, hospital discharge rate, 1

year survival were significantly better in the new program; 40% vs. 79% (p = 0.03) and 20.0% vs. 56% (p
= 0.01).
Increased referrals, standardized insertion and decannulation techniques, protocol-based
management and weaning of ECMO, were the keys to improved patient outcome.

Except for two

patients in Group 2, all of the patients who had profound cardiogenic shock or an episode of cardiac arrest
were placed on ECMO. These 2 patients were referred and evaluated for ECMO, but due to family
wishes and due to the likelihood of having irreversible brain injury, it was decided to withdraw care.
Continuous efforts to notify cardiologists about the ECMO program and keeping a good relationship, rapid
response to ‘code blue’ enabled the increase in referrals.

100% of patients who were placed on ECMO

were successfully weaned off and were either bridged to a ventricular assist device or recovered.
was possible because of the relatively low rate of major complications observed during ECMO.

This
Previous

studies reported a leg ischemia of 4 - 34%, renal failure requiring dialysis of 40%, bleeding complications
in 10%, neurological injury of 10 - 46% (Table 6).

None of our patients included in the study had a limb

ischemia, neurological injury or required hemodialysis during ECMO support. Routine use of the distal
perfusion catheter, monitoring the lower extremity saturation, open repair of the vessels, and
thrombectomy if needed enabled us to eliminate limb ischemia.

We do not recommend the use of smaller

femoral arterial cannulas (< 16 Fr) (17), as it may lead to increased shear stress and hemolysis, leading to
possibly both liver and kidney failure.

In addition, insufficient flow will result in inadequate

decompression of the heart, which will decrease the chance of the heart to recover.

We have not had

minor or major infection at the insertion site after decannulation, since the use of routine VAC dressing on
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the groin incision. Previous studies regarding treatment of cardiogenic shock due to AMI reported
ECMO weaning rate of 24 - 80%, hospital discharge rate of 34 - 76% (Table 5). Although the number of
patients included in our study is low, and the fact that our study included the patients who were supported
with ECMO for pLAD and LM lesions, the results were better than most reports.
Limitations of this study
This study was performed at a single center with retrospective data collection, and the number of
cases was relatively small. There were new physicians that were introduced into our practice and the
medical treatment besides the ECMO program may have had a substantial difference between the two
groups that could have resulted in the differences in the outcomes. To further elucidate the benefit of
ECMO in the treatment of AMI complicated with cardiogenic shock, a randomized, multicenter, controlled,
large-scale studies are needed to investigate the benefit of ECMO.
Conclusion
The new ECMO program significantly improved patient survival that developed cardiogenic
shock due to AMI caused by left main or proximal LAD lesion. The initiation of ECMO enabled to
improve the hemodynamics and organ perfusion with relatively small number of complications.
Acknowledgments
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Table 1: Patients’ baseline characteristics.

Data are expressed with mean ± standard deviation or number

(percentage).

Age (y)
Sex (male)
Body mass index (kg/m2)
Diabetes
Family history of coronary disease
Hyperlipidemia
Smoking
Hypertension
Previous MI
Renal injury (creatinine >1.5 g/dl)
Left main disease
Intra-aortic balloon pump support
Cardiopulmonary resuscitation
Ejection fraction (%)

Group 1 (n=15)
63.5 ± 13.9
12 (80%)
27.7 ± 6.2
8 (53%)
6 (40%)
4 (27%)
11 (73%)
7 (47%)
5 (33%)
6 (40%)
2 (13%)
14 (93%)
6 (40%)
30.4 ± 17.5

Group 2 (n=14)
63.4 ± 18.4
9 (64%)
29.3 ± 7.0
5 (36%)
3 (21%)
5 (36%)
9 (64%)
7 (50%)
2 (14%)
2 (14%)
3 (21%)
10 (71%)
5 (38%)
30.4 ± 19.0

p-value
0.99
0.34
0.52
0.34
0.28
0.60
0.60
0.86
0.23
0.12
0.56
0.12
0.81
1.00
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Table2: Treatment for the two groups

Percutaneous coronary intervention
Coronary artery bypass graft
ECMO support
PCI with ECMO support
CABG after ECMO

Group 1
11 (73%)
2 (13%)
1 (6.7%)
1 (6.7%)
0

Group 2
9 (64%)
4 (29%)
6 (42%)
0
1 (7.1%)

p-value
0.60
0.56
0.02
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Table 3. Laboratory data of patient on ECMO. Data are expressed mean ± standard deviation.

AST (IU/L)
ALT (IU/L)
Total bilirubin (mg/dl)
Creatinine (g/dl)
Lactate (mmol/L)
Vasoactive-inotropic score
(median, 25th – 75th percentile)

Pre ECMO
189 ± 301
341 ± 623
0.8 ± 0.4
1.2 ± 0.4
6.2 ± 5.0
104 ±121
(42, 17.5 - 234)

24hr
216 ± 268
142 ± 239
1.2 ± 0.7
1.0 ± 0.2
1.6 ± 0.8
1.3 ± 0.1
(0, 0 – 4)

Pre DC
127 ± 169
53 ± 28
1.2 ± 0.4
0.9 ± 0.2
2.4 ± 2.2

P-value
(pre vs. 24hr)
0.89
0.31
0.40
0.13
0.13

ALT: alanine aminotransferase; AST: aspartate aminotransferase, DC: decannulation.

0.09

P-value
(pre vs. DC)
0.33
0.35
0.14
0.13
0.25
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Table 4: Outcome of patients on ECMO (Group 2)
ECMO length
Bridge to ventricular assist device
Bridge to recovery
Death on ECMO
Sepsis
Limb ischemia
Neurological injury
Gastrointestinal bleed
Other major bleeding
Acute renal failure

9.8 ± 5.8 (1 - 18 days)
2 (33%)
4 (66%)
0 (0%)
1 (17%)
0 (0%)
0 (0%)
1 (17%)
1 (17%)
0 (0%)
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Table 5: Cause of Death

cardiogenic shock
arrhythmia
respiratory failure
bleeding
neurological injury

Group 1
4
3
1
1
0

Group 2
0
1
0
1
1
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Table 6: Previous studies regarding ECMO support for cardiogenic shock due to AMI.

Study

Year

N

Chen (18)

2006

36

Wean
off
ECMO*
69%

Sheu (19)

2010

46

78%

Chung (20)

2011

20

70%

Bermudez (21)

2011

33

Kim (22)

2012

27

82%

Tsao (23)

2012

33

82%

67%

Sakamoto (24)

2012

98

55%

33%

Wu (7)

2013

35

63%

40%

Tang (25)

2013

21

Demondion (26)

2014

77

Aoyama (27)

2014

38

Current

2014

6

100%

83%

67%

470

64%

56%

44%

Total

30 day
survival

Hospital
discharge
rate
48%

Dialysis

Infection

Sepsis

17%
50%

63%

Bleeding Neuro**

Leg ischemia
(distal limb perfusion)

53% ***

61%
64%

48%

1 yr.
survival

40%
48%

59%

40%

39%
37%

20%
12%

20%
24%

15% (when ischemic)

15%

64%
29%

7% (when ischemic)

46%

4% (routinely placed)
0%

0% (n/a)******

3%

7% (when ischemic)

46%

9% (n/a)

76%

76%

5% ***

10%

15%

39%

34%

46%

21%

3%

37%

37%

89%

56%

0%

33%

0%

17%

17%

0% (routinely placed)

47%

41%*****

31%

10%

36%

17%

10%

* includes patients who were bridged to transplant or mechanical assist device
** neurological injury
*** percentage of “renal failure”, **** percentage of “dialysis”, ******information not available

14%
9% (routinely placed)
50%

34% (n/a)
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Figure Legends
Figure 1. Summary of the outcome of the patients with cardiogenic shock due to AMI
Figure 2. Kaplan Meier survival curve of the patients with cardiogenic shock due to AMI
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